Similar articles for PMID: 36192003

Year	Number of Results
2011	1
2013	2
2014	3
2015	3
2016	5
2017	8
2018	9
2019	14
2020	20
2021	27
2022	39
2023	20
2024	1

1

Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.

Okada T, Matsuki T, Fushimi C, Okamoto I, Sato H, Kondo T, Tokashiki K, Ito T, Masubuchi T, Tada Y, Miura K, Hanyu K, Omura GO, Takahashi H, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Anticancer Res. 2022 Oct;42(10):4907-4912. doi: 10.21873/anticanres.15996. Anticancer Res. 2022. PMID: 36192003

2

Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.

Okamoto I, Tsukahara K, Sato H. Okamoto I, et al. Sci Rep. 2022 Feb 7;12(1):2025. doi: 10.1038/s41598-022-06084-z. Sci Rep. 2022. PMID: 35132165 Free PMC article.

3

Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.

Kondo T, Okamoto I, Sato H, Koyama N, Fushimi C, Okada T, Masubuchi T, Miura K, Matsuki T, Yamashita T, Omura G, Takahashi H, Tsukahara K. Kondo T, et al. Asia Pac J Clin Oncol. 2020 Dec;16(6):340-347. doi: 10.1111/ajco.13374. Epub 2020 Jun 23. Asia Pac J Clin Oncol. 2020. PMID: 32573033

4

Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.

Zargar M, McFarlane T, Chan KKW, Wong WWL. Zargar M, et al. Oncologist. 2018 Feb;23(2):225-233. doi: 10.1634/theoncologist.2017-0277. Epub 2017 Oct 11. Oncologist. 2018. PMID: 29021380 Free PMC article.

5

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Wada A, Enokida T, Okano S, Sato M, Tanaka H, Ueda Y, Fujisawa T, Takeshita N, Tanaka N, Tahara M. Wada A, et al. Eur J Cancer. 2023 May;184:30-38. doi: 10.1016/j.ejca.2023.02.011. Epub 2023 Feb 15. Eur J Cancer. 2023. PMID: 36898232

6

Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population.

Macia-Rivas L, Fernandez-Laguna CL, Alvarez-Asteinza C, Maray I, Carbajales-Alvarez M, Lozano-Blazquez A. Macia-Rivas L, et al. Anticancer Res. 2023 Apr;43(4):1681-1688. doi: 10.21873/anticanres.16320. Anticancer Res. 2023. PMID: 36974777

7

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.

Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K. Otsuki S, et al. Auris Nasus Larynx. 2022 Oct;49(5):834-844. doi: 10.1016/j.anl.2022.02.006. Epub 2022 Feb 26. Auris Nasus Larynx. 2022. PMID: 35232636

8

Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.

Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A. Economopoulou P, et al. Oral Oncol. 2020 Dec;111:105013. doi: 10.1016/j.oraloncology.2020.105013. Epub 2020 Sep 23. Oral Oncol. 2020. PMID: 32977184

9

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.

Pei R, Shi Y, Lv S, Dai T, Zhang F, Liu S, Wu B. Pei R, et al. JAMA Netw Open. 2021 May 3;4(5):e218065. doi: 10.1001/jamanetworkopen.2021.8065. JAMA Netw Open. 2021. PMID: 33956130 Free PMC article.

10

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.

Wakasaki T, Yasumatsu R, Uchi R, Taura M, Matsuo M, Komune N, Nakagawa T. Wakasaki T, et al. Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23. Auris Nasus Larynx. 2020. PMID: 31128940

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

132 results

Results by year